DelistingJul 22, 2026, 04:51 PM
20/20 Biolabs Receives Nasdaq Delisting Notice for Bid Price Non-Compliance
AI Summary
20/20 Biolabs, Inc. received a notice from Nasdaq regarding non-compliance with the $1.00 minimum bid price rule, having traded below this threshold for 30 consecutive business days. The company has been granted a 180-day period, until January 13, 2027, to regain compliance. Additionally, the company entered into a 120-day standstill agreement with Streeterville Capital, LLC, preventing the conversion of Series E preferred stock into common stock unless the common stock trades at least 10% greater than the Nasdaq Minimum Price.
Key Highlights
- Received Nasdaq notice for non-compliance with $1.00 minimum bid price rule.
- Non-compliance period was from June 3, 2026, to July 16, 2026.
- Granted 180-day compliance period until January 13, 2027, to regain compliance.
- Must maintain $1.00 closing bid price for 10 consecutive days to regain compliance.
- Entered a 120-day Standstill Agreement with Streeterville Capital, LLC.
- Streeterville agreed not to convert Series E preferred stock during standstill period.
- Standstill terminates if common stock trades 10% above Nasdaq Minimum Price.
Price Impact
More from AIDX